16:17 uur 12-03-2021

Altasciences voert preklinische studies uit ter ondersteuning van Verve Therapeutics ‘genbewerkingsmethode voor hart- en vaatziekten

LAVAL, Quebec– (BUSINESS WIRE) – Altasciences is er trots op preklinische onderzoeken te hebben uitgevoerd voor Verve Therapeutics die de ontwikkeling en vooruitgang van Verve’s benadering van genbewerking voor de behandeling van hart- en vaatziekten ondersteunen. Het team van Altasciences in Seattle voerde intraveneuze preklinische onderzoeken uit, waaronder ondersteunende analyses van farmacodynamische markers en DNA-bewerking van de hele lever, bij niet-menselijke primaten, die aantonen dat een enkele intraveneuze infusie van de geneditor van Verve een vermindering van 59% van het bloed met lage dichtheid lipoproteïne-cholesterol opleverde (LDL-C) na twee weken, die langer dan zes maanden na de behandeling is gehandhaafd. Er werden geen bijwerkingen gemeld tijdens het onderzoek en in onderzoeken met primaire menselijke hepatocyten werd duidelijk bewijs van on-target editing waargenomen.

Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease

LAVAL, Quebec–(BUSINESS WIRE)– Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing, in non-human primates, that show that a single intravenous infusion of Verve’s gene editor achieved a 59% reduction in blood low-density lipoprotein cholesterol (LDL-C) at two weeks, which has been maintained beyond six months post treatment. No adverse events were reported during the study and in studies of primary human hepatocytes, clear evidence of on-target editing was observed.

We are excited to have supported the advancement of Verve’s gene editors for cardiovascular disease, and to have contributed to the development of an entirely new approach to treating heart disease, which remains the leading cause of death among men and women worldwide,” says Mike Broadhurst, General Manager of Altasciences’ preclinical facility.

More information on Verve Therapeutics’ program can be found here.

About Altasciences

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Contacts

Julie-Ann Cabana

Altasciences
+1 514 601-9763
jcabana@altasciences.com

Check out our twitter: @NewsNovumpr